The Subcellular Localization of cyclin A Regulates Apoptosis in Cardiomyocytes

点击翻译按钮获取中文摘要

Doxorubicin (Dox) is an anticancer agent which has the side effect of cardiac toxicity. However, the precise molecular mechanism of doxorubicin-induced myocardial apoptosis is still unknown. We have previously reported that cyclin A/cdk2 kinase activity, which is one of the cell cycle regulators, is mediated hypoxia-induced apoptosis in cardiomyocytes. Because apoptosis typically begins in the cytoplasm in the proliferating cells, we tested the hypothesis that the subcellular localization of cyclin A determines the apoptotic fate. Primary rat cardiomyocytes were exposed to doxorubicin and increased apoptosis dose-dependently (10-5 to 10-7M) evaluated by TUNEL method and the number of viable cells. The cyclin A protein level assessed by immunoblot analysis accumulated with a maximum response after 6 hours treatment in cardiomyocytes. Also, doxorubicin increased in the activity of cyclin A-and cdk2-associated kinase by histone-H1 kinase assay. By immnohistochemistry, cyclin A was cytoplasm in cardiomyocytes, however, cyclin A was nuclear in proliferating condition of fibroblasts. To test whether the cyclin A-associated kinase was the effector for apoptosis, cardiomyocytes were infected by dominant-negative cdk2 adenovirus (dncdk2). The apoptosis by doxorubicin(10-6M) was significantly reduced (cont. 4.8± 1.8%, Dox. 46.2±4.0%, Dox+dncdk2 25.8±6.0%), suggesting that cyclin A/cdk2 kinase activity play significant roles in the doxorubicin induced apoptosis. In conclusion, these findings confirm that the activation of cyclin A in cytoplasm mediates doxorubicin-induced apoptosis in cardiomyocytes.